Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH229 plus daclatasvir in chronic hepatitis C (Phase II/III)
CTR20182539Phase 3Completed
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aoxibuvir, daclatasvir in hepatitis C virus infection, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd.. Started Jan 2019; status: completed.
02
Drugs
aoxibuvirdaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20182539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182539.